MX353786B - Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas. - Google Patents

Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas.

Info

Publication number
MX353786B
MX353786B MX2014009722A MX2014009722A MX353786B MX 353786 B MX353786 B MX 353786B MX 2014009722 A MX2014009722 A MX 2014009722A MX 2014009722 A MX2014009722 A MX 2014009722A MX 353786 B MX353786 B MX 353786B
Authority
MX
Mexico
Prior art keywords
methods
rotavirus
making
subunit vaccines
compositions
Prior art date
Application number
MX2014009722A
Other languages
English (en)
Other versions
MX2014009722A (es
Inventor
R Simonson Randy
F Bey Russell
Reddy Sirigireddy Kamesh
Matthew Hause Benjamin
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2014009722A publication Critical patent/MX2014009722A/es
Publication of MX353786B publication Critical patent/MX353786B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a polipéptidos antigénicos o antígenos de rotavirus que provocan una respuesta inmune contra los rotavirus en un animal o en un ser humano. Composiciones que comprenden dichos polipéptidos de los rotavirus. Métodos de vacunación contra los rotavirus. Conjuntos de elementos que pueden usarse con dichos métodos y con dichas composiciones. Vectores de expresión novedosos para producir vacunas basadas en dichos polipéptidos antigénicos.
MX2014009722A 2012-02-14 2013-02-14 Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas. MX353786B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598624P 2012-02-14 2012-02-14
PCT/US2013/026179 WO2013123219A1 (en) 2012-02-14 2013-02-14 Rotavirus subunit vaccines and methods of making and use thereof

Publications (2)

Publication Number Publication Date
MX2014009722A MX2014009722A (es) 2015-02-20
MX353786B true MX353786B (es) 2018-01-29

Family

ID=47755047

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014009722A MX353786B (es) 2012-02-14 2013-02-14 Vacunas de subunidades de rotavirus, metodos de preparacion y uso de las mismas.

Country Status (22)

Country Link
US (1) US9446117B2 (es)
EP (1) EP2814508B1 (es)
JP (1) JP6149240B2 (es)
KR (1) KR102087458B1 (es)
CN (1) CN104203274B (es)
AR (2) AR089995A1 (es)
AU (1) AU2013221479B2 (es)
BR (1) BR112014020025B1 (es)
CA (1) CA2864106C (es)
DK (1) DK2814508T5 (es)
EA (1) EA034564B1 (es)
ES (1) ES2632429T3 (es)
HK (1) HK1200326A1 (es)
HU (1) HUE033858T2 (es)
LT (1) LT2814508T (es)
MX (1) MX353786B (es)
NZ (1) NZ628282A (es)
PH (1) PH12014501795A1 (es)
PL (1) PL2814508T3 (es)
PT (1) PT2814508T (es)
SI (1) SI2814508T1 (es)
WO (1) WO2013123219A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
RU2649132C1 (ru) * 2017-08-03 2018-03-29 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Способ получения активного начала вакцины против ротавирусной инфекции белка FliCVP6VP8
CN108864260A (zh) * 2018-07-17 2018-11-23 昆明学院 非结构蛋白nsp4、重组杆状病毒液及制备、粘膜佐剂
CN109306007B (zh) * 2018-09-26 2021-10-08 华中农业大学 抗猪繁殖与呼吸综合征病毒nsp4蛋白基因工程抗体及应用
CN116438202A (zh) * 2020-10-05 2023-07-14 勃林格殷格翰动物保健美国有限公司 包含圆环病毒科衣壳蛋白的融合蛋白及其构成的嵌合病毒样颗粒
CN114875047A (zh) * 2022-05-27 2022-08-09 江苏三仪生物工程有限公司 一种优化的猪轮状病毒外衣壳蛋白vp4的重组表达及应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US5147639A (en) * 1990-06-19 1992-09-15 Ambico, Inc. Type-c rotavirus cultures and uses therefor
US5298244A (en) 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
BE1006085A3 (fr) 1992-07-31 1994-05-10 Univ Bruxelles Vecteur de clonage.
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
EP0833670B1 (en) 1995-06-14 2003-09-03 Baylor College Of Medicine Vaccine against rotavirus infection comprising peptides of viral enterotoxin nsp4
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751228B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Vaccin polynucleotidique bovin pour voie intradermique
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751229B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique notamment contre la pathologie respiratoire des bovins
FR2751224B1 (fr) 1996-07-19 1998-11-20 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies respiratoires et de reproduction des porcs
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
DE69826124T3 (de) 1997-06-30 2007-10-11 Institut Gustave Roussy Verabreichung der nukleinsäure in den quergestreiften muskel
DE69942249D1 (de) 1998-05-07 2010-05-27 Univ Bruxelles Auf cytotoxinen basierendes biologisches einschlusssystem
FR2778858B1 (fr) 1998-05-20 2000-06-16 Oreal Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique
US6716431B1 (en) 1998-05-29 2004-04-06 Wyeth Holdings Corporation Differential cytotoxicity of alternative forms of rotavirus nonstructural protein 4
US6187319B1 (en) 1998-06-01 2001-02-13 University Of Massachusetts Cross-protective rotavirus vaccine
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
FR2801607B1 (fr) 1999-11-26 2001-12-28 Merial Sas Pneumovirus du canard et vaccins correspondants
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
US6867353B2 (en) 2000-02-12 2005-03-15 Exploregen Inc. Production method of recombinant rotavirus structural proteins and vaccine composition
EP1349571A4 (en) * 2000-11-03 2005-02-16 Baylor College Medicine ROTAVIRUS ENTEROTOXIN NSP4 AND METHOD FOR ITS USE
JP2006512368A (ja) 2002-12-19 2006-04-13 アクゾ・ノベル・エヌ・ベー 乳汁を介して母親由来抗体を伝達する三価ワクチン
WO2005009462A2 (en) 2003-07-24 2005-02-03 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
WO2006007555A2 (en) * 2004-07-01 2006-01-19 Children's Medical Center Corporation ¨ Rotavirus antigens
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
BRPI0504441A (pt) * 2005-10-20 2007-06-26 Fundacao Oswaldo Cruz vetores de expressão plasmidial contendo regiões especìficas para a expressão de proteìnas ou epìtopos recombinantes de rotavìrus e astrovìrus, processo de produção dos insumos para geração de imunobiológicos para diagnóstico
CA2644195A1 (en) * 2006-03-03 2007-09-13 Merial Limited Mycoplasma hyopneumoniae vaccine
EP2297186B1 (en) 2008-05-29 2018-08-29 The Government of The United States of America, as represented by the Secretary, Department of Health and Human Services, Expression and assembly of human group c rotavirus-like particles and uses thereof
EP2310511B1 (fr) 2008-07-18 2015-01-14 Sanofi Pasteur Vecteur auto replicatif depourvu de gene de resistance a un antibiotique
SI2475384T1 (sl) 2009-09-10 2016-12-30 Merial, Inc. Nove formulacije cepiva, ki obsegajo adjuvante, vsebujoče saponin

Also Published As

Publication number Publication date
AU2013221479A1 (en) 2014-08-28
PL2814508T3 (pl) 2017-09-29
AU2013221479B2 (en) 2017-06-08
NZ628282A (en) 2016-08-26
AR089995A1 (es) 2014-10-01
DK2814508T5 (da) 2017-06-12
KR102087458B1 (ko) 2020-03-10
AR126891A2 (es) 2023-11-29
PT2814508T (pt) 2017-07-19
BR112014020025A2 (pt) 2017-07-04
JP6149240B2 (ja) 2017-06-21
SI2814508T1 (sl) 2017-10-30
EA034564B1 (ru) 2020-02-20
WO2013123219A1 (en) 2013-08-22
EP2814508B1 (en) 2017-04-12
KR20140123592A (ko) 2014-10-22
EP2814508A1 (en) 2014-12-24
CA2864106C (en) 2017-10-17
JP2015508776A (ja) 2015-03-23
CA2864106A1 (en) 2013-08-22
CN104203274A (zh) 2014-12-10
HK1200326A1 (en) 2015-08-07
US20130209507A1 (en) 2013-08-15
DK2814508T3 (da) 2017-05-22
BR112014020025A8 (pt) 2022-07-12
LT2814508T (lt) 2017-06-26
PH12014501795B1 (en) 2014-11-17
HUE033858T2 (en) 2018-01-29
MX2014009722A (es) 2015-02-20
CN104203274B (zh) 2017-09-08
ES2632429T3 (es) 2017-09-13
EA201400914A1 (ru) 2014-12-30
PH12014501795A1 (en) 2014-11-17
BR112014020025B1 (pt) 2022-09-27
US9446117B2 (en) 2016-09-20

Similar Documents

Publication Publication Date Title
MX2021000193A (es) Selección de epítopos de vacunas personalizadas contra el cáncer.
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX360415B (es) Vectores poxvirales recombinantes que expresan proteinas tanto de rabia como de ox40, y vacunas hechas a partir de los mismos.
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es) Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
MX2016008640A (es) Formulaciones de vacuna de vial unico.
PH12015501716A1 (en) Anti-mycoplasma spp. subunit vaccine
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
EA201891124A3 (ru) Новые мукозные адъюванты и системы доставки
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
NZ700470A (en) Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
WO2016191641A3 (en) Methods for enhancing antigen-specific immune responses using combination therapy comprising papillomavirus capsid antigens
MX2017011322A (es) Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus.
MX348137B (es) Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
IN2014CN00547A (es)
MX361804B (es) Vacunas genéticas contra el virus hendra y el virus nipah.
CL2013002782A1 (es) Formulación inmunogénica para inducir la respuesta inmune en un sujeto que comprende una mezcla de bacterias no patógenas que expresan cada una un segmento hipervariable de la proteína m de diferentes streptococcus pyogenes; uso de la formulación para producir una vacuna; método para producir vacuna
AU2019268149A1 (en) Live attenuated heterologous vaccine for Leptospira
TN2010000500A1 (en) Leishmania vaccine using sand fly salivary immunogen
MX2021001641A (es) Identificacion de proteinas inmunogenicas para el control de ectoparasitos.
PL411372A1 (pl) Bakteriofagi nadające się do wytwarzania szczepionek oraz sposób ich otrzymywania

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: MERIAL, INC.

FG Grant or registration